# Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07589517/  
OnCo record `nct07589517` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC in colorectal cancer, run by Beijing Biotech, now recruiting.

## Summary

Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07589517 by Beijing Biotech, with 48 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUO-CAR-NK-CEA/GCC and Lymphodepletion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07589517
- Phase: 1/2
- Setting: A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer
- Sponsor: Beijing Biotech
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07589517: https://clinicaltrials.gov/study/NCT07589517

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct07589517.json